Cinclus Pharma: First patient dosed in phase III study - Redeye

Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivotal phase III study with linaprazan glurate in erosive GERD. We see this as an important operational milestone confirming that the program is progressing according to plan, positioning Cinclus well ahead of the topline results expected in H2 2026e.

Länk till analysen i sin helhet: https://www.redeye.se/research/1129711/cinclus-pharma-first-patient-dosed-in-phase-iii-study?utm_source=finwire&utm_medium=RSS